Shares of Genocea Biosciences Inc. (NASDAQ:GNCA) shot up 4.4% during trading on Friday . The company traded as high as $4.57 and last traded at $4.53, with a volume of 304,077 shares trading hands. The stock had previously closed at $4.34.

A number of brokerages have recently commented on GNCA. Zacks Investment Research cut Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday. FBR & Co reaffirmed a “buy” rating and issued a $17.00 price target on shares of Genocea Biosciences in a research note on Friday, April 1st. Stifel Nicolaus upped their price target on Genocea Biosciences from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, April 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a research note on Friday, April 1st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $18.13.

The company’s market cap is $125.28 million. The company has a 50-day moving average price of $4.20 and a 200 day moving average price of $4.36.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. On average, equities analysts expect that Genocea Biosciences Inc. will post ($1.74) EPS for the current fiscal year.

A hedge fund recently raised its stake in Genocea Biosciences stock. AWM Investment Company Inc. raised its position in shares of Genocea Biosciences Inc. (NASDAQ:GNCA) by 45.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 715,000 shares of the company’s stock after buying an additional 222,900 shares during the period. AWM Investment Company Inc. owned approximately 2.54% of Genocea Biosciences worth $3,768,000 as of its most recent filing with the SEC.

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.